Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A pioneering collaborative mouse study from an international team of researchers including DPAG's Associate Professor Ana Domingos published in Nature offers new therapeutic avenues for reducing visceral fat stores, which have been associated with cardiovascular disease and multiple types of cancer.

Visceral fat supports various fundamental functions, such as reproduction. However, when it is too abundant, it produces unhealthy levels of proteins and hormones that negatively affect neighbouring tissues and organs. In this study authors reveal the first known neuro-immune process by which brain signals instruct immune function in visceral fat stores. © dustinhumes_photography
Visceral fat stores

Obesity has been linked to an increased risk of 13 types of cancer, including breast and colorectal, the two most prevalent cancers, together with cardiovascular disease, one of the leading causes of death worldwide. 

The most harmful type of obesity is caused by excessive accumulation of visceral fat, commonly called "deep" fat. While the most visible fat stores, or subcutaneous fat, are located directly under the skin, visceral fat is the fat stored inside our abdominal cavity, surrounding our vital internal organs. Normal amounts of visceral fat support a number of fundamental functions, such as reproduction. However, too much visceral fat produces unhealthy levels of proteins and hormones that negatively impact neighbouring tissues and organs, and it can be very difficult to eliminate.

DPAG’s Associate Professor Ana Domingos has collaborated with researchers from the Champalimaud Research Programme in Portugal and the Max Planck Institute for Metabolism Research in Germany to explore the mechanisms that naturally reduce visceral fat with the aim of uncovering potential clinical applications to benefit patients suffering from obesity. In doing so, they have uncovered the first known neuro-immune process by which brain signals instruct immune function in visceral fat stores. This discovery offers several new approaches to tackle obesity and its related illness.

Visceral fat is a complex tissue made up of many different cell types in addition to fat cells, including immune cells. The team was particularly interested in a type of adipose-resident immune cell called ILC2s (Type 2 Innate Lymphoid Cells) because they are essential to the immune functions in many tissues and organs, including the overall health of fat tissue. What was previously unknown was which cells control ILC2s in visceral fat and how these cells communicate at the molecular level. Previous related research in the lung had shown that the nervous system directly controls ILC2 activity, but in this new study, neurons and immune cells did not communicate. Instead, researchers found there is an unexpected critical mediator of neuro-immune communication in visceral fat: Mesenchymal cells (MSCs), which had previously been widely considered to be a ‘bystander’. Until recent decades, the widespread view was that MSCs are mainly involved in producing the ‘scaffolding’ of the tissue, over which other cells would carry out the rest of the work. Scientists have since discovered that MSCs in fact carry out several important and active roles within tissue.

Prof Domingos said: “We demonstrated that sympathetic neurons in visceral fat provide local signals to MSCs, and that those in turn control ILC2s. This triad of cells seems to control fat mass and could be pharmacologically exploited for the development of new anti-obesity drugs.”

The team were also able to demonstrate what area of the brain is ultimately responsible for driving this neural activity at the visceral fat stores. Researchers found that a region within the hypothalamus (called PVH), situated near the base of the brain, is the control centre of a diverse set of processes ranging from metabolism to reproduction, gastrointestinal and cardiovascular functions. Co-last author Henrique Veiga-Fernandes describes this finding as “The first clear example of a cross-body neuronal circuit that translates brain information into an obesity-related immune function.”

According to the team, these results provide not one but several potential approaches for visceral-fat-burning manipulations. First author Filipa Cardoso points out that “The multistep axis we identified offers many access points into visceral fat metabolism. We can now start thinking about how to use this new knowledge to fight visceral obesity and hence reduce the risk of cardiovascular disease and cancer.” Furthermore, the team’s results both verify and feed into a newly identified field of research. As Prof Domingos says: “This collaborative work body embraces neuroimmunometabolism as an emerging research area.”

The full paper “Neuro-mesenchymal units control ILC2 and obesity via a brain–adipose circuit” is available to read in Nature.

This text is adapted from a press release written by Liad Hollender, Science writer and editor of the CCU Communication, Outreach and Events team.

Similar stories

Key cause of type 2 diabetes uncovered

Research led by Dr Elizabeth Haythorne and Professor Frances Ashcroft reveals high blood glucose reprograms the metabolism of pancreatic beta-cells in diabetes. They have discovered that glucose metabolites, rather than glucose itself, are key to the progression of type 2 diabetes. Glucose metabolites damage pancreatic beta-cell function, so they are unable to release enough of the hormone insulin. Reducing the rate at which glucose is metabolised, and these glucose metabolites build up, can prevent the effects of hyperglycaemia.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

Updating the circuit maps of the sympathetic neural network

A new review from Professor Ana Domingos’ lab and colleagues offers a fresh modern viewpoint on sympathetic neurons and their relation to immune cells and obesity.

New Pfizer grant paves the way to a better understanding of how body fat is controlled

Professor Ana Domingos has been awarded a highly competitive independent research grant from Pfizer to discover ‘the role of Sympathetic-associated Perineurial barrier Cells in obesity’.

Collaborative MRC grant paves the way to new therapeutic targets for stress and anxiety disorders

Dr Armin Lak, Associate Professor Ed Mann and Professor Zoltán Molnár have been awarded a £733K Project Grant from the Medical Research Council on “Orexinergic projections to neocortex: potential role in arousal, stress and anxiety-related disorders”.